drugset / Trial / NCT07493031
A PhaseⅠ Study of HW252001 in Healthy Subjects
Phase 1
Not yet recruiting
98 enrolled
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 1, randomized, double-blind, placebo-controlled, Single/multiple ascending doses (SAD/MAD) study of HW252001 in healthy subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and Pharmacodynamics of HW252001.
Timeline
- Start
- 2026-03-31
- Primary completion
- 2026-12-11
- Completion
- 2026-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HW252001 | Unknown | — | Oral |